Lung Cancer Clinical Trial 20213057

[LCID Study Number: 20213057]

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (Lung-MAP Sub-study)

This Lung-MAP treatment trial will study the effect of AMG 510 in treating stage IV or recurrent KRAS G12C-positive non-squamous non-small cell lung cancer.

Disease/Condition: Lung Cancer

Department: Hematology and Oncology

Location(s): Beverly Hospital; Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421

View NCT ID 04625647 on ClinicalTrials.gov
Protocol #: 20213057
Study Coordinator(s): Brendan J. Connell
Trial Phase: Sponsor Initiated Study Phase 2